AGM
ALLO icon

Alpine Global Management’s Allogene Therapeutics ALLO Stock Holding History

Alpine Global Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18,267
Closed -$115K – 147
2022
Q4 		$115K Buy
+18,267
New +$169K 0.04% 202
2020
Q3 		– Sell
-150,000
Closed -$6.42M – 238
2020
Q2 		$6.42M Buy
+150,000
New +$5.42M 1.13% 10

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alpine Global Management's ALLO Position: Q1 2023 in Review

Alpine Global Management sold out of Allogene Therapeutics (ALLO) in Q1 2023, closing a stake of 18,267 shares — an estimated $115K sold.

Alpine Global Management first reported a position in ALLO in Q2 2020 and held it in 2 quarters. The position peaked at $6.42M in Q2 2020. 176 funds tracked by Wall St. Rank hold ALLO as of Q1 2023.

  • Alpine Global Management reported no remaining Allogene Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 18,267 Allogene Therapeutics shares in Q1 2023, an estimated $115K.
  • Alpine Global Management first reported a position in Allogene Therapeutics in Q2 2020 and held it in 2 quarters.
  • Alpine Global Management's Allogene Therapeutics position peaked at $6.42M in Q2 2020.
  • 176 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.